1. |
Nso N, Antwi-Amoabeng D, Beutler BD, et al. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: a systematic review and meta-analysis. World J Cardiol, 2020, 12(11): 584-598.
|
2. |
Guo X, Wang H, Zhou J, et al. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. Thorac Cancer, 2020, 11(2): 475-480.
|
3. |
Courand PY, Bouali A, Harbaoui B, et al. Myocarditis: Uncommon but severe toxicity of immune checkpoint inhibitors. Bull Cancer, 2019, 106(11): 1050-1056.
|
4. |
Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol, 2018, 19(12): 1579-1589.
|
5. |
Lyon AR, Yousaf N, Battisti NML, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol, 2018, 19(9): e447-e458.
|
6. |
Saygin D, Ghosh N, Reid P. Immune checkpoint inhibitor-associated myositis: a distinct form of inflammatory myopathy. J Clin Rheumatol, 2022, 28(7): 367-373.
|
7. |
Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Toxicol, 2021, 17(4): 411-424.
|
8. |
Osinga TE, Oosting SF, van der Meer P, et al. Immune checkpoint inhibitor-associated myocarditis: case reports and a review of the literature. Neth Heart J, 2022, 30(6): 295-301.
|
9. |
Wu NC, Feng YH, Kuo YH, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated cardiovascular toxicities. Acta Cardiol Sin, 2022, 38(1): 39-46.
|
10. |
赵艳艳, 张会鲜, 孟路华, 等. 基于美国FDA不良事件报告系统数据库的免疫检查点抑制剂致胆管炎风险分析. 药物不良反应杂志, 2022, 24(8): 424-428.
|
11. |
Makunts T, Saunders IM, Cohen IV, et al. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep, 2021, 11(1): 17324.
|
12. |
Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet, 2018, 391(10124): 933.
|
13. |
Zhou YW, Zhu YJ, Wang MN, et al. Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management. Front Pharmacol, 2019, 10: 1350.
|
14. |
Jing Y, Zhang Y, Wang J, et al. Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy. J Natl Cancer Inst, 2021, 113(10): 1396-1404.
|
15. |
Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol, 2018, 71(16): 1755-1764.
|
16. |
石宏伟, 唐恒, 韩光, 等. 免疫检查点抑制剂所致心肌炎研究进展. 中华肿瘤防治杂志, 2022, 29(16): 1159-1164, 1183.
|
17. |
Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol, 2018, 4(12): 1721-1728.
|
18. |
Dong H, Qi Y, Kong X, et al. PD-1/PD-L1 inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism. Front Pharmacol, 2022, 13: 835510.
|
19. |
Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses, 2022, 14(2): 192.
|
20. |
Tay WT, Fang YH, Beh ST, et al. Programmed cell death-1: programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro. Int J Mol Sci, 2020, 21(7): 2399.
|
21. |
Portolés Hernández A, Blanco Clemente M, Escribano García D, et al. Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report. Cardiovasc Diagn Ther, 2021, 11(4): 1013-1019.
|
22. |
Zhang L, Zlotoff DA, Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation, 2020, 141(24): 2031-2034.
|